Abbott's $23 Billion Bet on Exact Sciences and the Test That Finds Colon Cancer at Home

Abbott Laboratories paid a stunning premium for Exact Sciences, a company that had never turned a consistent profit, and Wall Street blinked.

By Carry and Conquer Publications

On November 20, 2025, Abbott announced a definitive agreement to acquire Exact Sciences Corporation for $105 per share in cash, a 22% premium to the prior closing price, valuing the Madison, Wisconsin company at approximately $21 billion in equity and $23 billion including the assumption of roughly $1.8 billion in net debt. The deal, which closed on March 23, 2026 after receiving shareholder and regulatory approval, stands as the largest diagnostics acquisition in history and the largest medtech transaction since Pfizer bought Seagen for $43 billion in 2023. It is also the biggest deal of CEO Robert Ford's tenure at Abbott: a declaration that the company's next era belongs not to cardiovascular stents or glucose monitors, but to a cardboard box mailed back from a bathroom in Dubuque.

What Abbott Actually Bought

The centerpiece of the acquisition is Cologuard, a noninvasive stool DNA test for colorectal cancer screening. Patients collect a stool sample at home, seal it in a proprietary kit, and mail it to an Exact Sciences laboratory, where technicians screen for abnormal DNA and blood markers associated with colorectal cancer or precancerous polyps. The test requires no bowel preparation, no sedation, no clinical visit, and no fasting. A negative result earns a clean three years before the next required screening. A positive result triggers a colonoscopy. The test received simultaneous FDA approval and national Medicare coverage in August 2014, the first medical device or diagnostic to receive both at the same time, setting Exact Sciences apart from every other diagnostics company in the country.

Since launch, more than 16 million completed screenings have been processed through Cologuard, with the company reporting that the test has detected 525,000 people with advanced precancerous lesions. In 2024, Exact Sciences generated $2.76 billion in revenue, up 10% year-over-year, and was tracking toward more than $3 billion in 2025. But Exact had also reported a net loss of more than $1 billion in 2024, driven largely by non-cash impairments and the enormous cost of running a direct-to-patient sales and marketing operation. The company had never achieved consistent GAAP profitability despite a decade in the market.

Cologuard is not the only asset Abbott acquired. Exact Sciences also owns Oncotype DX, a genomic breast cancer recurrence test that has reportedly spared more than one million women from unnecessary chemotherapy by predicting the likelihood of cancer returning. It owns Oncodetect, a molecular residual disease test that monitors for cancer recurrence after treatment. And it owns Cancerguard, a multi-cancer early detection blood test capable of screening for 50 cancer types, including some of the deadliest and least detectable, such as pancreatic, ovarian, and esophageal cancer, from a single blood draw. Abbott CEO Robert Ford has described these products as answering three foundational questions in oncology diagnostics: Do I have cancer? What is the best treatment? And is my cancer in remission?

The Kevin Conroy Story

The Exact Sciences that Abbott acquired bears almost no resemblance to the company Kevin Conroy joined in 2009. The company had been founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber, focused on developing a noninvasive colon cancer test. By the time Conroy arrived as President and CEO, recruited from Third Wave Technologies, a molecular diagnostics firm he had led to acquisition by Hologic, Exact Sciences' share price had spent years trading below one dollar and the company was widely expected to either be acquired or exit the market.

Conroy's bet was personal in the deepest sense. He grew up in Flint, Michigan, with a close group of friends. After joining Exact Sciences, four of those friends were diagnosed with colon cancer. Today, only one is still alive. The scientific foundation he chose to build on came from a meeting in March 2009 with Dr. David Ahlquist of the Mayo Clinic, who convinced Conroy that DNA technology could accurately detect colorectal cancer from a stool sample. Conroy established the formal collaboration with Mayo Clinic that produced Cologuard's development and the landmark 10,000-patient clinical trial whose results were published in The New England Journal of Medicine.

Under his 16-year leadership, Conroy oversaw more than ten acquisitions, including the $2.8 billion purchase of Genomic Health in 2019, which brought Oncotype DX into the portfolio, and the acquisition of Thrive Earlier Detection, which seeded the liquid biopsy pipeline that became Cancerguard. The company grew from three employees to more than 7,000. Exact Sciences announced Conroy would stay on through the transition period in an advisory role before departing following the close.

Why the Premium Looks Counterintuitive

Even analysts who endorsed the deal's strategic logic raised eyebrows at the price. Bernstein analyst Christian Moore noted the $105 offer valued Exact at a level it had not traded at since 2023 and warned that Abbott's earnings and multiples would face near-term pressure. Moore went further, questioning whether Abbott, a company without an oncology business of its own, would benefit fully from Exact's precision oncology tests. Abbott acknowledged the deal would be dilutive to adjusted EPS through 2027 and has already revised its full-year 2026 EPS guidance lower by $0.20 per share to reflect the acquisition's drag.

The financial logic is complex. Exact Sciences owns and operates the laboratories where its tests are processed, meaning it collects reimbursement directly from insurers and CMS on a per-test basis. Abbott's traditional model sells instruments and reagents to hospitals, capturing only a fraction of downstream revenue. Acquiring Exact shifts Abbott toward a more direct reimbursement model with higher gross margins per transaction, a structural shift that analysts at West Monroe called meaningful. TD Cowen managing director Joshua Jennings argued that Abbott's primary care sales infrastructure, including the roughly 1,000 field representatives supporting the FreeStyle Libre continuous glucose monitor franchise, could dramatically accelerate Cologuard penetration, since colorectal cancer screening is driven overwhelmingly through primary care physician visits. Abbott noted that combining Exact's commercial platform with its own would effectively double its diagnostics total addressable market, from approximately $60 billion to more than $120 billion.

But the contrarian case deserves a serious hearing. Cologuard held approximately 13% of the $18 billion colorectal cancer screening market at the time of announcement, a dominant position but still a minority of a market where colonoscopy remains the clinical gold standard. A positive Cologuard result still requires a confirmatory colonoscopy, which creates an awkward dynamic where Cologuard can serve as a funnel to the very procedure it positions itself against. The $592 Medicare reimbursement rate set for Cologuard Plus, the updated version with improved sensitivity and 40% fewer false positives launched with Medicare coverage in early 2025, represents a 16% increase over the original Cologuard's $508 rate, but CMS reimbursement policy and the Medicare Advantage transition schedule remain live variables. Abbott disclosed it expects a return on invested capital in the high single digits within six years, and acknowledged that return will come primarily from revenue growth, not cost-cutting.

The Diagnostic Arms Race

The Abbott-Exact Sciences deal lands in the middle of a broader reorganization of the American diagnostics industry. Quest Diagnostics spent much of 2024 and early 2025 executing an aggressive series of outreach lab acquisitions from hospital health systems, including the completion of its acquisition of University Hospitals' outreach laboratory services business in Ohio in January 2025, and the announcement of a joint venture with Corewell Health in Michigan in August 2025. Quest's co-lab partnership revenues grew from roughly $300 million in 2019 to $800 million by 2025, with the company forecasting the segment would cross $1 billion. Labcorp has pursued parallel consolidation, acquiring ambulatory lab businesses from community health systems and building deeper presence in specialty testing.

What neither Quest nor Labcorp possessed was a leading consumer-facing cancer screening brand with FDA approval, direct Medicare coverage, and a mail-in logistics infrastructure that had processed millions of tests. Cologuard sits at the intersection of consumer healthcare behavior and clinical oncology in a way that routine blood draws do not. That brand recognition, built in part through direct-to-consumer advertising campaigns and the distinctive orange Cologuard box, is something Abbott is inheriting rather than building. Abbott's Stifel analyst Rick Wise described the combination as akin to Abbott's management of the FreeStyle Libre franchise: a platform with strong consumer brand power that the company could scale globally using its primary care distribution.

International expansion is the growth thesis that makes the valuation defensible over a multi-year horizon. Exact Sciences' revenue is almost entirely U.S.-based. Abbott operates in more than 160 countries and has deep relationships with healthcare systems across developed and emerging markets where colonoscopy capacity is far more limited than in the United States. In countries where gastroenterology infrastructure is sparse, a mail-in stool DNA test with demonstrated 92% sensitivity for colorectal cancer detection offers a genuinely different clinical and logistical proposition.

The Question the Deal Leaves Open

Abbott has acquired a company that bet its future on making cancer screening frictionless enough that people would actually do it. The clinical insight behind Cologuard has always been simpler than the financial story: colorectal cancer, the second leading cause of cancer death in the United States with approximately 153,000 new diagnoses per year, is one of the most preventable cancers in existence if caught early, and roughly one-third of eligible American adults had never completed any screening at all. The problem was not clinical. It was behavioral. Cologuard's thesis was that the box you mail from home would reach people the gastroenterology appointment would not.

That thesis has been validated. Whether it can be validated at $23 billion is the question Abbott is now living inside. The deal closed on March 23, 2026, with Exact Sciences delisted from the Nasdaq on March 20. Cologuard's double-digit growth in Abbott's first Q1 2026 results alongside early Cancerguard sales suggest the core franchise is performing. But the ROIC target of high single digits within six years requires sustained revenue growth in a market where blood-based multi-cancer tests, including Cancerguard itself, are converging with stool-based testing, payer acceptance timelines remain uncertain, and the liquid biopsy field includes formidable competitors such as Guardant Health. Robert Ford is betting $23 billion that the orange box in your bathroom becomes the opening chapter of something much larger. The diagnostics industry will be watching whether Abbott can write the rest of the story.